http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-117650-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-60
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-14
filingDate 2019-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ae3c1833a57acf5d76d6fedccddbeb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0304c21482fb98f4bed57eceb1e8ffa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0b1e20b4c0105f44503bd0be32c381b
publicationDate 2021-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-117650-A1
titleOfInvention POST-PROCESSING OF BISPECIFIC ANTIBODIES CONSTRUCTS
abstract The present provides an improved manufacturing method for the production of bispecific antibody constructs, comprising at least two binding domains. The method comprises at least the method comprising a step of refolding the construct, in which one or more of the domains comprise a disulfide bond, and in which the construct is contacted with a refolding buffer to refold the construct to its native form, the buffer comprising (i) a redox and / or oxidizing agent having a concentration of at least 0.1 mM and (ii) a chaotropic agent having a concentration> 1 M, and in which the pH of the refolding corresponds to +/- 4.5 of the pI value of the first domain or +/- 4.0 of the pI value of the entire construct. Claim 1: A method of purification of a bispecific antibody construct, the construct comprising: a first domain having a pl of 5.0 to 9.5 that binds to a tumor target; a second domain that binds to an extracellular epitope of the human and Macaca CD3e chain; and optionally a third domain comprising two polypeptide monomers, each comprising a hinge, a CH2 domain and a CH3 domain, wherein said two polypeptide monomers are fused to each other via a peptide linker, wherein the construct comprises at least one open disulfide bridge, in which one or more of the domains comprise a disulfide bond, the method characterized in that it comprises a step of refolding the construct, in which the construct is contacted with a refolding buffer to refold the construct in its native form, the buffer (i) comprising a redox and / or oxidizing agent having a concentration of at least 0.1 mM where the redox agent is selected from the group consisting of reduced glutathione / oxidized glutathione, cysteine / cystine, cysteine / cysteamine, cysteine / cystamine, dithiothreitol (DTT), b-mercaptoethanol, and glutathione, and where the oxidizing agent is selected from the group consisting of copper (II), oxygen dissolved ene and (L) -dehydroascorbic acid (DHA), and (ii) a chaotropic agent having a concentration in the range of 1 M to 2.5 M, where the chaotropic agent is selected from the group consisting of urea, dimethyl urea, methylurea, ethylurea, organic solvents and guanidinium, and wherein the pH of the refolding buffer corresponds to +/- 4.5 of the pI value of the first domain or +/- 4.0 of the pI value of the entire construct.
priorityDate 2018-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5862
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID418354341
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12254
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556339
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419881948
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419485715
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457578503
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557851
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID424084
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65359
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549069
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6992103
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID977
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID32838
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425499957
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23978
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413862368
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6058
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587403
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1567
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11719
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7293
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1176
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID440667
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419578874
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419576385
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19001
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523291
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559045
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID124886

Total number of triples: 59.